Lallemand Health Solutions and Kirin Holdings Company, Limited are pleased to announce their strategic partnership aimed at enhancing the visibility and market reach of IMMUSE®, the one of the most documented postbiotic for immune support. This collaboration leverages the distinct strengths of both companies to bring advanced immune health solutions to consumers worldwide.
Evidence-rich ingredient
IMMUSE®, developed by Kirin Holdings Company, Limited, is an award-winning postbiotic, with its immune function supported by patent-protected research. It is a clinically researched lactic acid bacteria that supports immune health through a unique mode of action. This heat-inactivated Lactococcus lactis strain Plasma directly activates key immune cells called plasmacytoid dendritic cells, offering comprehensive immune support by stimulating both innate and adaptive immune responses.
IMMUSE® has been extensively studied, with 15 clinical studies demonstrating its efficacy in supporting immune health. Key findings in the area include: a significant decrease in cough days and sore throat severity compared to placebo [Shibata, 2016], a reduction in cold-like symptoms and cumulative incidence days [Suzuki, 2015], enhanced immune response, including up-regulation of antiviral gene expression levels and increased secreted IgA levels in saliva [Fujii, 2017], promotion of exercise performance by supporting the immune system in healthy athletes [Komano, 2018 & 2023]. IMMUSE® is available in a variety of dosage forms, making it easy to integrate into a daily routine.
Daiji Niwa, Executive Officer, General Manager of the Health Science Business Department at Kirin Holdings, adds: "With over 130 years of fermentation expertise and nearly 40 years of immunity research, Kirin Holdings has developed the innovative postbiotic IMMUSE®. We trust Lallemand is the ideal partner to advance this mission and promote health and wellness."
Isabelle Champié, Vice-President of Sales and Marketing at Lallemand Health Solutions, states: "With 90 years of expertise in microbial solutions, we offer science-backed, customized probiotic and postbiotic formulas for nutritional supplements, food and beverage applications and pet supplements. IMMUSE® from Kirin Holdings will be a great addition to our portfolio, bringing a documented solution for immune health to meet the increasing market demand."
Consumer trends and market growth
The global postbiotic market is expected to reach USD 3 billion by 2031, with a CAGR of +6.8% from 2022 to 2031. The postbiotic supplements market is estimated to be valued at USD 10.8 million in 2024, with a CAGR growing +10.9% from 2024 to 2034, reaching USD 30.5 million. Consumers are increasingly aware of the link between digestive health and immune health, with 73% recognising this connection. The top health benefits of postbiotics are gut health, immune support, and sports performance.
For more information, please visit Lallemand Health Solutions’ team during Vitafoods Europe in Barcelona from May 20-22, 2025 at booth #4C26 to discuss how you can bring IMMUSE® in your market, or contact healthsolutions@lallemand.com
